Clinical Pharmacology in Drug Development · 2017 · 16 citations · 9 references
PharmacyClinical PharmacokineticsPharmacologyClinical PharmacologyPharmacodynamicsWomen's Health PharmacotherapyContraceptive PharmacotherapyMultiple Sclerosis PharmacotherapyArea Under The Plasma Concentration-time CurveCombined Oral Contraceptive TreatmentConcentration-time Curve CharacterizationMultiple Sclerosis NeuroprotectionOral Contraceptive PillsPharmacokinetics Of Hormonal ContraceptivesPlasma Concentration - Time ProfilePlasma Concentration-time Analysis
Delayed-release dimethyl fumarate (DMF) is an oral therapy for relapsing multiple sclerosis with anti-inflammatory and neuroprotective properties. This 2-period crossover study was conducted to evaluate the potential for drug-drug interaction between DMF (240 mg twice daily) and a combined oral contraceptive (OC; norgestimate 250 μg, ethinyl estradiol 35 μg). Forty-six healthy women were enrolled; 32 completed the study. After the lead-in period (OC alone), 41 eligible participants were randomized 1:1 to sequence 1 (OC and DMF coadministration in period 1; OC alone in period 2) or sequence 2 (regimens reversed). Mean concentration profiles of plasma norelgestromin (primary metabolite of norgestimate) and ethinyl estradiol were superimposable following OC alone and OC coadministered with DMF, with 90% confidence intervals of geometric mean ratios for area under the plasma concentration-time curve over the dosing interval and peak plasma concentration contained within the 0.8-1.25 range. Low serum progesterone levels during combined treatment confirmed suppression of ovulation. The pharmacokinetics of DMF (measured via its primary active metabolite, monomethyl fumarate) were consistent with historical data when DMF was administered alone. No new safety concerns were identified. These results suggest that norgestimate/ethinyl estradiol-based OCs may be used with DMF without dose modification.
9
Alastair Compston, Alasdair Coles · The Lancet · 2008 · 4.3K citations
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold, Ludwig Kappos, Douglas L. Arnold et al. · New England Journal of Medicine · 2012 · 1.7K citations · Full text
Medicine, Neurology, Pharmacotherapy +17